Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).

[1]  L. Reggiani Bonetti,et al.  Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery? , 2017, World journal of gastroenterology.

[2]  J. Park,et al.  What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy? , 2015, Cancer research and treatment : official journal of Korean Cancer Association.

[3]  D. Shibata,et al.  Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Eun Ho Kim,et al.  The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells. , 2014, Oncology reports.

[5]  R. Greil,et al.  Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. , 2014, Anticancer research.

[6]  J. Bergh,et al.  LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE) , 2014 .

[7]  N. Petrelli,et al.  Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Tait,et al.  RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. , 2014, European journal of cancer.

[9]  Jeffrey W. Clark,et al.  Mutational and Clinical Predictors of Pathologic Complete Response in the Treatment of Locally Advanced Rectal Cancer , 2014, Journal of Gastrointestinal Cancer.

[10]  J. Coffey,et al.  KRAS mutation does not predict the efficacy of neo-adjuvant chemoradiotherapy in rectal cancer: a systematic review and meta-analysis. , 2013, Surgical oncology.

[11]  R. Winterhalder,et al.  Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  P. Kienle,et al.  Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. , 2012, The Lancet. Oncology.

[13]  R. Winterhalder,et al.  Neoadjuvant radiotherapy (RT) combined with capecitabine (Cape) and sorafenib (Sor) in patients with locally advanced, K-ras-mutated rectal cancer (LARC): A phase I/II trial (SAKK 41/08). , 2012 .

[14]  C. Lathia,et al.  Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial , 2011, Journal of clinical pharmacology.

[15]  M. Bracko,et al.  Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study , 2011, Radiation oncology.

[16]  T. Ruhstaller,et al.  Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Christophe Hennequin,et al.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Ellis,et al.  Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. , 2010, International journal of radiation oncology, biology, physics.

[19]  T. Beißbarth,et al.  KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  J. Robertson,et al.  Sorafenib and radiation: A promising combination in colorectal and pancreas cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  K. Sheahan,et al.  A Simplified Tumor Regression Grade Correlates with Survival in Locally Advanced Rectal Carcinoma Treated with Neoadjuvant Chemoradiotherapy , 2008, Annals of Surgical Oncology.

[22]  Bernard Leduc,et al.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[24]  Rainer Fietkau,et al.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Mazumdar,et al.  Long-term Oncologic Outcome Following Preoperative Combined Modality Therapy and Total Mesorectal Excision of Locally Advanced Rectal Cancer , 2005, Annals of surgery.

[26]  S. Kong,et al.  The role of Raf-1 in radiation resistance of human hepatocellular carcinoma Hep G2 cells. , 2004, Oncology reports.

[27]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[28]  L. Goodglick,et al.  Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis. , 2004, Advances in cancer research.

[29]  M. Sigmund,et al.  Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  O. Dworak,et al.  Pathological features of rectal cancer after preoperative radiochemotherapy , 1997, International Journal of Colorectal Disease.